AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6136132 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 + H2-antagonists
Number of subjects: 15
Study 30977467 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine viral load (VL) monitoring
Number of subjects: 1973
Study 30977467 — intervention group
Group type: COMPARATOR
Intervention: Discretionary viral load (VL) monitoring
Number of subjects: 1973
Study 29582920 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Continued (TC)
Number of subjects: 28
Study 29582920 — intervention group
Group type: COMPARATOR
Intervention: Training Stopped (TS)
Number of subjects: 28
Study 29582920 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective physical performance
Number of subjects: 28
Study 26072396 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment screening for TPMT variants with dose reduction (50% for heterozygous carriers, 0%-10% for homozygous carriers)
Number of subjects: 783
Study 26072396 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 783
Study 26072396 — intervention group
Group type: COMPARATOR
Intervention: Both intervention and control groups
Number of subjects: 783
Study 23718725 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefan® (test)
Number of subjects: 18
Study 23718725 — intervention group
Group type: COMPARATOR
Intervention: Coartem® (reference)
Number of subjects: 18
Study 20800445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective screening for eligibility over 8 weeks
Number of subjects: 74
Study 20800445 — intervention group
Group type: COMPARATOR
Intervention: Retrospective chart review
Number of subjects: 74
Study 19550356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 157
Study 19550356 — intervention group
Group type: EXPERIMENTAL
Intervention: ABPM
Number of subjects: 157
Study 17580509 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde fixation
Number of subjects: 0
Study 17580509 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymol storage
Number of subjects: 0
Study 17580509 — intervention group
Group type: COMPARATOR
Intervention: Freshly extracted teeth
Number of subjects: 0
Study 12872102 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable stiffness enteroscopy
Number of subjects: 67
Study 12872102 — intervention group
Group type: COMPARATOR
Intervention: Conventional enteroscopy with overtube
Number of subjects: 67
Study 12872102 — intervention group
Group type: COMPARATOR
Intervention: Conventional enteroscopy without overtube
Number of subjects: 67
Study 10861154 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior lumbar plexus block with 0.4 ml/kg bupivacaine, 0.5%, with epinephrine
Number of subjects: 60
Study 10861154 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia without lumbar plexus block (control group)
Number of subjects: 60
Study 9351691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmed K4 system
Number of subjects: 7
Study 8477964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (13 to 15 mg/kg/day)
Number of subjects: 146
Study 8477964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 3757764 — intervention group
Group type: EXPERIMENTAL
Intervention: lipo‐PGE1 (5 micrograms/day)
Number of subjects: 20
Study 3757764 — intervention group
Group type: COMPARATOR
Intervention: PGE1CD (40 micrograms/day)
Number of subjects: 20
Study 31931848 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin 10 mg/kg once daily for 3 days
Number of subjects: 11500
Study 31931848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11500
Study 30148871 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 165
Study 30148871 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean albuminuria at 38 months
Number of subjects: 165
Study 30148871 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-averaged albuminuria cut-off of 900 mg/day
Number of subjects: 165
Study 28290800 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/HCT (Val/HCT) - group I
Number of subjects: 50
Study 28290800 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril/HCT (Quin/HCT) - group II
Number of subjects: 50
Study 28290800 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time DBP variability in group I
Number of subjects: 50
Study 28290800 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude and speed of morning DBP surge in group I
Number of subjects: 50
Study 24131075 — intervention group
Group type: EXPERIMENTAL
Intervention: CP 3 g (Group B)
Number of subjects: 32
Study 24131075 — intervention group
Group type: EXPERIMENTAL
Intervention: CP 3 g and vitamin C 500 mg (Group C)
Number of subjects: 32
Study 24131075 — intervention group
Group type: COMPARATOR
Intervention: No supplement (Group A)
Number of subjects: 32
Study 24131075 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C 500 mg (Group D)
Number of subjects: 32
Study 22564464 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalant users
Number of subjects: 697
Study 22564464 — intervention group
Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 697
Study 19717481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5993
Study 19717481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5993
Study 18407003 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based smoking-cessation program plus nicotine patch
Number of subjects: 1866
Study 18407003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative assignment of tailoring depth factors
Number of subjects: 1866
Study 15839181 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved BP goal of less than 130/85 mm Hg
Number of subjects: 977
Study 15839181 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved BP goal of less than 130/80 mm Hg
Number of subjects: 977
Study 15839181 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of dyslipidemia
Number of subjects: 977
Study 15839181 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of overweight, obesity, or morbid obesity
Number of subjects: 977
Study 15839181 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of tobacco use
Number of subjects: 977
Study 12428224 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pulse prednisolone, methotrexate, plus sulfasalazine
Number of subjects: 110
Study 12428224 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine alone
Number of subjects: 110
Study 10898263 — intervention group
Group type: EXPERIMENTAL
Intervention: Overstride (−8% PSF)
Number of subjects: 18
Study 10898263 — intervention group
Group type: EXPERIMENTAL
Intervention: Understride (+8% PSF)
Number of subjects: 18
Study 10898263 — intervention group
Group type: COMPARATOR
Intervention: Normal stride frequency
Number of subjects: 18
Study 10898263 — intervention group
Group type: EXPERIMENTAL
Intervention: Second downhill run (all groups)
Number of subjects: 18
Study 10898263 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 18
Study 8893636 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution computed tomography (HRCT)
Number of subjects: 13
Study 1924640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam four times daily
Number of subjects: 80
Study 1924640 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg fluoxetine every morning
Number of subjects: 80
Study 1924640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam four times daily and 60 mg fluoxetine every morning
Number of subjects: 80
Study 1924640 — intervention group
Group type: COMPARATOR
Intervention: Placebo four times daily
Number of subjects: 80
Study 1924640 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 80
Study 7043341 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 gel (2 ml containing 0.5 mg PGE2)
Number of subjects: 50
Study 7043341 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (gel without PGE2)
Number of subjects: 50
Study 7043341 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 gel (0.5 mg) in subsequent open study
Number of subjects: 50
Study 31849306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (phone calls)
Number of subjects: 120
Study 31849306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (text messages)
Number of subjects: 120
Study 31849306 — intervention group
Group type: COMPARATOR
Intervention: Group III (control, standard advice at discharge)
Number of subjects: 120
Study 29229898 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepabulin (10,000 units) intravenously injected intraoperatively, daily for 1 week, weekly for 1 month, and then once per month
Number of subjects: 87
Study 29229898 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepabulin (10,000 units)
Number of subjects: 87
Study 25440110 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusions prepared from 2 g of C citratus leaf powder once daily for 30 days
Number of subjects: 105
Study 25440110 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusions prepared from 4 g of C citratus leaf powder once daily for 30 days
Number of subjects: 105
Study 25440110 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusions prepared from 8 g of C citratus leaf powder once daily for 30 days
Number of subjects: 105
Study 25169962 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 6
Study 22971904 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive walking-like leg movement (PWM) for 25 minutes at 1 Hz
Number of subjects: 13
Study 22971904 — intervention group
Group type: COMPARATOR
Intervention: Quiet standing (QS) for 25 minutes
Number of subjects: 13
Study 21060071 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3-acid ethyl esters-90 (1 g/d for 1 year)
Number of subjects: 3851
Study 21060071 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 3851
Study 17714578 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 125 mg
Number of subjects: 12
Study 17714578 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg
Number of subjects: 12
Study 17714578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16416000 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicyclo tablets
Number of subjects: 148
Study 16416000 — intervention group
Group type: COMPARATOR
Intervention: Hugan tablets
Number of subjects: 148
Study 12549799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacteria Bb12 supplement
Number of subjects: 148
Study 12549799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacteria Bb12 and Streptococcus thermophilus supplement
Number of subjects: 148
Study 12549799 — intervention group
Group type: COMPARATOR
Intervention: Infant formula without supplement (Control)
Number of subjects: 148
Study 9625220 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 21
Study 9625220 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg caffeine
Number of subjects: 21
Study 7656463 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting followed by a one-year vegetarian diet
Number of subjects: 27
Study 7656463 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27
Study 2658673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous analgosedation with midazolam (0.1 mg/kg) and fentanyl (2 micrograms/kg)
Number of subjects: 0
Study 7454568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine HCl, 5-day course before surgery
Number of subjects: 0
Study 31608962 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi polysaccharide vaccine
Number of subjects: 80
Study 31608962 — intervention group
Group type: COMPARATOR
Intervention: Inactivated hepatitis A vaccine
Number of subjects: 80
Study 30785903 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised response technique (RRT)
Number of subjects: 0
Study 30785903 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmatched count technique (UCT)
Number of subjects: 0
Study 30785903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nominative technique (NT)
Number of subjects: 0
Study 30785903 — intervention group
Group type: EXPERIMENTAL
Intervention: False consensus bias (FCB)
Number of subjects: 0
Study 30785903 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of bear part use
Number of subjects: 0
Study 28933576 — intervention group
Group type: EXPERIMENTAL
Intervention: Special training in recovery-oriented approach for mental health nurses
Number of subjects: 0
Study 28933576 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26352252 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-gauge needle for facial injections
Number of subjects: 20
Study 24054381 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene mesh (PM) implant
Number of subjects: 100
Study 24054381 — intervention group
Group type: COMPARATOR
Intervention: Anterior colporraphy with or without synthetic sling (Control)
Number of subjects: 100
Study 21483004 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel plus high-dose calcitriol (DN-101)
Number of subjects: 953
Study 21483004 — intervention group
Group type: COMPARATOR
Intervention: docetaxel plus prednisone
Number of subjects: 953
Study 19144565 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser evoked potentials (LEPs) stimulation on the second and third fingers
Number of subjects: 34
Study 19144565 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser evoked potentials (LEPs) stimulation
Number of subjects: 34
Study 19144565 — intervention group
Group type: COMPARATOR
Intervention: Control group (sex- and age-matched subjects)
Number of subjects: 34
Study 17723081 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant ferrous sulfate with MMF (days -6 to 0)
Number of subjects: 12
Study 17723081 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-separated ferrous sulfate with MMF (days 9 to 16)
Number of subjects: 12
Study 17723081 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide iron complex with MMF (days -6 to 0)
Number of subjects: 12
Study 17723081 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide iron complex administered 2 hours after MMF (days 9 to 16)
Number of subjects: 12
Study 17723081 — intervention group
Group type: COMPARATOR
Intervention: Control phase (MMF alone, days 1-8)
Number of subjects: 12
Study 17011960 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonosafe
Number of subjects: 240
Study 17011960 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonojet
Number of subjects: 240
Study 17011960 — intervention group
Group type: COMPARATOR
Intervention: Goldmann
Number of subjects: 240
Study 12615629 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 39
Study 10589629 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg/mL ropivacaine
Number of subjects: 63
Study 10589629 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/mL ropivacaine
Number of subjects: 63
Study 10589629 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 63
Study 10589629 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritramid (opioid)
Number of subjects: 63
Study 8933852 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of alfentanil (0.75 mg bolus followed by 0.36 mg/h for 24 h)
Number of subjects: 20
Study 8933852 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of alfentanil (0.36 mg/h for 24 h)
Number of subjects: 20
Study 1680361 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 7 micrograms kg‐1 followed by infusion of 3 micrograms kg‐1 h‐1
Number of subjects: 20
Study 1680361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1 micrograms kg‐1 followed by 0.4 micrograms kg‐1 h‐1
Number of subjects: 20
Study 1680361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both fentanyl and sufentanil
Number of subjects: 20
Study 1680361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and Sufentanil
Number of subjects: 20
Study 7088753 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 7088753 — intervention group
Group type: EXPERIMENTAL
Intervention: Antrafenine
Number of subjects: 0
Study 7088753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29405923 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based mobile-supported cognitive-behavioral intervention
Number of subjects: 204
Study 29405923 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition with unrestricted access to usual care
Number of subjects: 204
Study 27831985 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 458
Study 27831985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 24218528 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (transdermal patch of 9.5 mg/day)
Number of subjects: 31
Study 24218528 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 31
Study 24218528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 23076435 — intervention group
Group type: EXPERIMENTAL
Intervention: Freiburg monosyllabic test with hearing aids in background noise (CCITT-noise; 65/60 dB signal-noise ratio)
Number of subjects: 217
Study 23076435 — intervention group
Group type: EXPERIMENTAL
Intervention: Freiburg monosyllabic test without hearing aids in background noise (CCITT-noise; 65/60 dB signal-noise ratio)
Number of subjects: 217
Study 23076435 — intervention group
Group type: EXPERIMENTAL
Intervention: Freiburg monosyllabic test with hearing aids without background noise
Number of subjects: 217
Study 23076435 — intervention group
Group type: EXPERIMENTAL
Intervention: Freiburg monosyllabic test without hearing aids without background noise
Number of subjects: 217
Study 23076435 — intervention group
Group type: COMPARATOR
Intervention: Freiburg monosyllabic test (control group)
Number of subjects: 217
Study 20538557 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg sibutramine once daily for 19 months
Number of subjects: 60
Study 20538557 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg sibutramine once daily for 19 months
Number of subjects: 60
Study 18490787 — intervention group
Group type: EXPERIMENTAL
Intervention: athletic ability condition
Number of subjects: 51
Study 18490787 — intervention group
Group type: EXPERIMENTAL
Intervention: technical soccer ability condition
Number of subjects: 51
Study 18490787 — intervention group
Group type: COMPARATOR
Intervention: control condition
Number of subjects: 51
Study 16291416 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 plus pioglitazone
Number of subjects: 281
Study 16291416 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide plus pioglitazone
Number of subjects: 281
Study 16291416 — intervention group
Group type: COMPARATOR
Intervention: BIAsp 30 monotherapy
Number of subjects: 281
Study 12461758 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based 10-week strength training intervention (N=34)
Number of subjects: 68
Study 12461758 — intervention group
Group type: COMPARATOR
Intervention: Home exercise control (N=34)
Number of subjects: 68
Study 10498359 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and subcutaneous epinephrine with bovine topical thrombin (1000 U/ml)
Number of subjects: 42
Study 10498359 — intervention group
Group type: COMPARATOR
Intervention: Control group (no epinephrine, only bovine topical thrombin)
Number of subjects: 42
Study 10498359 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 8983684 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary caffeine restriction
Number of subjects: 13
Study 8983684 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 13
Study 8983684 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 13
Study 2016228 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 27
Study 2016228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7062378 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous flow resectoscope
Number of subjects: 36
Study 7062378 — intervention group
Group type: COMPARATOR
Intervention: Conventional resectoscope
Number of subjects: 36
Study 31835040 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostatin (highest quartile)
Number of subjects: 3463
Study 31835040 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostatin (1-SD higher log-transformed)
Number of subjects: 3463
Study 31835040 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostatin (added to basic model)
Number of subjects: 3463
Study 30829203 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 80
Study 30829203 — intervention group
Group type: COMPARATOR
Intervention: Anti‐tuberculosis regime (Control)
Number of subjects: 80
Study 28266591 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive hydration (20 ml/kg bolus followed by 3 ml/kg/h)
Number of subjects: 60
Study 28266591 — intervention group
Group type: COMPARATOR
Intervention: Standard hydration (10 ml/kg bolus followed by 1.5 ml/kg/h)
Number of subjects: 60
Study 28266591 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive hydration
Number of subjects: 60
Study 28266591 — intervention group
Group type: COMPARATOR
Intervention: Standard hydration
Number of subjects: 60
Study 25864739 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) at 0.067 mg/kg/day
Number of subjects: 22
Study 25864739 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 24007461 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (from <5 mg/L to ≥5 mg/L, n = 45)
Number of subjects: 327
Study 24007461 — intervention group
Group type: COMPARATOR
Intervention: Group 4 (from ≥5 mg/L to ≥5 mg/L, n = 80)
Number of subjects: 327
Study 21411210 — intervention group
Group type: EXPERIMENTAL
Intervention: Motiva System with educational videos, motivational messages, and questionnaires
Number of subjects: 92
Study 21411210 — intervention group
Group type: COMPARATOR
Intervention: Motiva System + self monitoring of blood pressure, heart rate, and weight
Number of subjects: 92
Study 19288937 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented group (11 patients)
Number of subjects: 38